arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has successfully generated potent antibody antagonists of Nav1.7, using its proprietary SIMPLE Antibody™ technology.
Genmab A/S will announce today at its Annual General Meeting a new pre-clinical antibody program, HuMax-cMet,as well as a novel next generation bispecific antibody technology.
Speaking today at the plenary session of the 7th Annual European Antibody Congress in Geneva, Dr. Anat Cohen-Dayag, President and CEO of Compugen Ltd., presented Compugen's Antibody Target Discovery Platform, one of the Company's predictive discovery platforms for novel therapeutic targets.
Oxford University Press and the Chinese Antibody Society are pleased to announce their new partnership to launch the journal Antibody Therapeutics this spring.
Precision Antibody announced today its selection by Science Applications International Corporation-Frederick to provide antibody and antigen characterization, including surface plasmon resonance analysis, for the National Cancer Institute's "Clinical Proteomic Technologies for Cancer" initiative. A goal of the CPTC is to develop a standardized resource of very high-quality, renewable reference antibodies generated against cancer-related proteins. The antibodies will be made available to proteomics researchers, along with characterization data and other information intended to support replication and standardization.
A new anthrax antibody engineered by scientists at The University of Texas at Austin protects and defends against inhalation anthrax without the use of antibiotics and other more expensive antibodies.
Responding to a request from a Chinese biotechnology company working closely with officials in China, Medarex, Inc. and the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) have shipped to Beijing a sample of the fully human antibody to SARS developed by Medarex and MBL/UMMS.
Tanox, Inc. announced today that it has begun dosing patients in its Phase 2 clinical trial of TNX-355 for the treatment of the human immunodeficiency virus (HIV).